Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PHGE

PHGE - BiomX Inc Stock Price, Fair Value and News

$6.48-0.47 (-6.76%)
Market Closed

Price Targets

PHGE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PHGE Price Action

Last 7 days

111.8%

Last 30 days

224.0%

Last 90 days

-36.6%

Trailing 12 Months

-56.3%

PHGE RSI Chart

PHGE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PHGE Valuation

Market Cap

9.9M

Price/Earnings (Trailing)

-0.26

Price/Sales (Trailing)

38.75

EV/EBITDA

-0.09

Price/Free Cashflow

-0.22

PHGE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

PHGE Fundamentals

PHGE Revenue

Revenue (TTM)

158.0K

PHGE Earnings

Earnings (TTM)

-37.4M

Earnings Growth (Yr)

-195.06%

Earnings Growth (Qtr)

-51.83%

PHGE Profitability

EBT Margin

-23649.37%

Return on Equity

-356.43%

Return on Assets

-142.83%

Free Cashflow Yield

-462.66%

PHGE Investor Care

Shares Dilution (1Y)

59.58%

Diluted EPS (TTM)

25.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20220000
2021158.0K158.0K158.0K158.0K
2020000158.0K
20190887.1K522.6K0
20180000
Get all data in R, Python etc through our Historical Stock Data APIs

About BiomX Inc

PHGE
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
 CEO
 WEBSITEbiomx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES54

BiomX Inc Frequently Asked Questions

PHGE is the stock ticker symbol of BiomX Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of BiomX Inc is 9.89 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PHGE's fair value in chart for subscribers.

The fair value guage provides a quick view whether PHGE is over valued or under valued. Whether BiomX Inc is cheap or expensive depends on the assumptions which impact BiomX Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PHGE.

As of Wed Jan 28 2026, PHGE's PE ratio (Price to Earnings) is -0.26 and Price to Sales (PS) ratio is 38.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PHGE PE ratio will change depending on the future growth rate expectations of investors.